On October 20, 2025, Summit Therapeutics Inc. reported its third-quarter financial results and announced the expansion of its ivonescimab clinical trials, highlighting a new study for colorectal cancer initiated on October 17, 2025. They also noted a 40% reduction in disease progression for lung cancer treatments compared to competitors, and plan to submit a Biologics License Application soon.